CEO and co-founder
Matthias Hackl graduated in the area of Biotechnology from the University of Natural Resources and Life Sciences Vienna (Boku) in 2012. His studies of microRNA function in mammalian cell lines and model systems of Ageing involved rotations through labs at the University of Georgia and Minnesota in the United States as well as University Bielefeld in Germany. Matthias has won two private company grants for developing applications of PCR and Flow Cytometry based microRNA quantification tools and was honored by the Austrian Association of Molecular Life Sciences and Biotechnology for his achievements during his PhD. He has authored 30 publications and two book chapters in the field of microRNA biology and held a one-year PostDoc position in microRNA-based cell engineering at the Vienna Institute of Biotechnology before joining TAmiRNA. Matthias Hackl is also co-founder of Remute Bio GmbH, founded in 2016.
Otto Kanzler has more than 30 years experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma- industry, specified for strategic and economic issues. He is a serial entrepreneur having founded and co-founded several companies, all of which are still active - CEO / CFO of Remute Bio GmbH (founded 2016), co-founder and interim CEO / CFO of Phoenestra GmbH (founded 2015), Advisor of DirectSens GmbH (since 2015), co-founder and CFO of Syconium Lactic Acid GmbH (founded 2014), co-founder and CFO of TAmiRNA GmbH (founded 2012), co-founder and CEO of Evercyte GmbH und Chorus GmbH, (both founded 2011). Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993).
Senior Project Manager
Hanna Dellago holds a master’s degree in genetics and microbiology from the University of Vienna and a PhD degree in Biotechnology from the University of Natural Resources and Life Sciences Vienna (BOKU). Her PhD and PostDoc studies in the lab of Prof. Johannes Grillari focused on the functional characterization of proteins and microRNAs in cellular and organismal senescence, and she involved stages at the University of Toronto, Canada, and the University of Dundee, Scotland. Hanna Dellago joined TAmiRNA in 2016 as scientific writer. Since 2018, she is senior project manager at TAmiRNA in charge of B2B and customer communication, conceptualization and processing of contract research projects.
Scientific advisor and co-founder
Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009. In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).
Scientific advisor and co-founder
Johannes Grillari has more than 10 years of experience as a group leader in cellular and molecular aging research. Since 2006 he is associate professor at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. He did his PhD degree between 1996 and 1999 on senescence of endothelial cells and worked as a visiting scientist at the University of Dundee, Scotland, UK. He has authored and co-authored more than 63 scientific articles and book chapters, 6 patents, and was invited as speaker more than 70 times to international meetings. Furthermore, Johannes Grillari is co-founder and CSO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (founded 2015) and co-founder and scientific advisor of Remute Bio GmbH (2016).